The role of growth factor receptor pathways in human breast cancer cells adapted to long-term estrogen deprivation

被引:93
作者
Sabnis, GJ [1 ]
Jelovac, D [1 ]
Long, B [1 ]
Brodie, A [1 ]
机构
[1] Univ Maryland, Sch Med, Dept Pharmacol & Expt Therapeut, Hlth Sci Facil 1, Baltimore, MD 21201 USA
关键词
D O I
10.1158/0008-5472.CAN-04-4092
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
To study the long-term effects of estrogen deprivation on breast cancer, MCF-7Ca human estrogen receptor-positive breast cancer cells stably transfected with human aromatase gene were cultured in the steroid-depleted medium for 6 to 8 months until they had acquired the ability to grow. Proliferation of these cells (UMB-1Ca) was accompanied by increased expression of human epidermal growth factor receptor 2, increased activation of AKT through phosphorylation at Ser473 and Thr308, and increased invasion compared with parental MCF-7Ca cells. Estrogen receptor expression was also increased 5-fold. Although growth was inhibited by the antiestrogen fulvestrant, the IC50 was 100-fold higher than for parental MCF-7Ca cells. Aromatase inhibitor letrozole also inhibited growth at 10,000-fold higher concentration than required for MCF-7Ca cells, whereas anastrozole, exemestane, formestane, and tamoxifen were ineffective at 100 nmol/L. Growth of UMB-1Ca cells was inhibited by phosphatidylinositol 3-kinase inhibitor wortmannin (IC50 similar to 25 nmol/L) and epidermal growth factor receptor kinase inhibitor gefitinib (ZD 1839; IC50 similar to 10 mu mol/L) whereas parental MCF-7Ca cells were insensitive to these agents. Concomitant treatment of UMB-1Ca cells with the signal transduction inhibitors and anastrozole and tamoxifen restored their growth inhibitory effects. These studies show that estrogen deprivation results in up-regulation of growth factor signaling pathways, which leads to a more aggressive and hormone refractory phenotype. Cross-talk between ER and growth factor signaling was evident as inhibition of these pathways could restore estrogen responsiveness to these cells.
引用
收藏
页码:3903 / 3910
页数:8
相关论文
共 34 条
[1]   The "chemoinvasion assay": a tool to study tumor and endothelial cell invasion of basement membranes [J].
Albini, A ;
Benelli, R ;
Noonan, DM ;
Brigati, C .
INTERNATIONAL JOURNAL OF DEVELOPMENTAL BIOLOGY, 2004, 48 (5-6) :563-571
[2]  
Baum M, 2003, Cancer, V98, P1802
[3]   ESTROGENS IN PLASMA AND FATTY TISSUE FROM BREAST-CANCER PATIENTS AND WOMEN UNDERGOING SURGERY FOR NON-ONCOLOGICAL REASONS [J].
BLANKENSTEIN, MA ;
SZYMCZAK, J ;
DAROSZEWSKI, J ;
MILEWICZ, A ;
THIJSSEN, JHH .
GYNECOLOGICAL ENDOCRINOLOGY, 1992, 6 (01) :13-17
[4]  
Brodie AMH, 2002, BREAST CANCER: PROGNOSIS, TREATMENT, AND PREVENTION, P251
[5]   EFFECT OF AN AROMATASE INHIBITOR, 4-HYDROXY-4-ANDROSTENE-3,17-DIONE, ON ESTROGEN-DEPENDENT PROCESSES IN REPRODUCTION AND BREAST-CANCER [J].
BRODIE, AMH ;
SCHWARZEL, WC ;
SHAIKH, AA ;
BRODIE, HJ .
ENDOCRINOLOGY, 1977, 100 (06) :1684-1695
[6]   Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor α -: A new model for anti-estrogen resistance [J].
Campbell, RA ;
Bhat-Nakshatri, P ;
Patel, NM ;
Constantinidou, D ;
Ali, S ;
Nakshatri, H .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (13) :9817-9824
[7]   A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer [J].
Coombes, RC ;
Hall, E ;
Gibson, LJ ;
Paridaens, R ;
Jassem, J ;
Delozier, T ;
Jones, SE ;
Alvarez, I ;
Bertelli, G ;
Ortmann, O ;
Coates, AS ;
Bajetta, E ;
Dodwell, D ;
Coleman, RE ;
Fallowfield, LJ ;
Mickiewicz, E ;
Andersen, J ;
Lonning, PE ;
Cocconi, G ;
Stewart, A ;
Stuart, N ;
Snowdon, CF ;
Carpentieri, M ;
Massimini, G ;
Bliss, JM .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (11) :1081-1092
[8]   CD40-dependent activation of phosphatidylinositol 3-kinase/Akt pathway mediates endothelial cell survival and in vitro angiogenesis [J].
Deregibus, MC ;
Buttiglieri, S ;
Russo, S ;
Bussolati, B ;
Camussi, G .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (20) :18008-18014
[9]   Phosphoinositide 3-kinase signalling in breast cancer: how big a role might it play? [J].
Fry, MJ .
BREAST CANCER RESEARCH, 2001, 3 (05) :304-312
[10]   A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer [J].
Goss, PE ;
Ingle, JN ;
Martino, S ;
Robert, NJ ;
Muss, HB ;
Piccart, MJ ;
Castiglione, M ;
Tu, D ;
Shepherd, LE ;
Pritchard, KI ;
Livingston, RB ;
Davidson, NE ;
Norton, L ;
Perez, EA ;
Abrams, JS ;
Therasse, P ;
Palmer, MJ ;
Pater, JL .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (19) :1793-1802